Evidence map›Paper›PMID 38483479›Full record

ArticleMicrobiology spectrum2024

Unlocking the mechanism of action: a cost-effective flow cytometry approach for accelerating antimicrobial drug development.

Fabian Mermans, Hanna De Baets, Cristina García-Timermans, Wim Teughels, Nico Boon

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Fabian MermansCenter for Microbial Ecology and Technology, Faculty of Bioscience Engineering, Ghent University, Gent, Belgium.ORCID 0000-0003-2997-2885
Hanna De BaetsCenter for Microbial Ecology and Technology, Faculty of Bioscience Engineering, Ghent University, Gent, Belgium.
Cristina García-TimermansCenter for Microbial Ecology and Technology, Faculty of Bioscience Engineering, Ghent University, Gent, Belgium.ORCID 0000-0002-7052-1616
Wim TeughelsDepartment of Oral Health Sciences, KU Leuven & Dentistry (Periodontology), University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0001-7675-5643
Nico BoonCenter for Microbial Ecology and Technology, Faculty of Bioscience Engineering, Ghent University, Gent, Belgium.ORCID 0000-0002-7734-3103
Ghent University · BEKU Leuven · BE

Funding

Fonds Wetenschappelijk Onderzoek (FWO) G0B2719N
6 · The paper itself

Abstract

Antimicrobial resistance is one of the greatest challenges to global health. While the development of new antimicrobials can combat resistance, low profitability reduces the number of new compounds brought to market. Elucidating the mechanism of action is crucial for developing new antimicrobials. This can become expensive as there are no universally applicable pipelines. Phenotypic heterogeneity of microbial populations resulting from antimicrobial treatment can be captured through flow cytometric fingerprinting. Since antimicrobials are classified into limited groups, the mechanism of action of known compounds can be used for predictive modeling. We demonstrate a cost-effective flow cytometry approach for determining the mechanism of action of new compounds. Cultures of

Indexed as

Anti-Infective AgentsCephalothinAnti-Bacterial AgentsCost-Benefit AnalysisDrug DevelopmentFlow CytometryHumansAnti-Bacterial AgentsAnti-Infective AgentsCephalothinActinomyces viscosusantibioticsantimicrobialsflow cytometryFusobacterium nucleatummechanism of actionmode of actionpredictive modelingrandom forestsaliva

Identifiers

PMID38483479
PMCPMC10986550
OpenAlexW4393411132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.